Mayukh Sukhatme serves as President of Roivant Pharma, a business unit of Roivant Sciences. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. Roivant Pharma companies include Myovant, Axovant, Arbutus, Urovant, Enzyvant, Dermavant, Genevant, Metavant, Immunovant, Respivant, Altavant, and Aruvant. Dr. Sukhatme joined Roivant in 2015 and previously served as Chief Business Officer.
From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned an M.D. from Harvard Medical School and a B.S. in Biology and a B.S. in Literature from MIT.